MedTrace Logo

Phase III Cat-PAD Study

NCT01620762 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1408

Last updated 2018-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.

Conditions

  • Rhinoconjunctivitis

Interventions

DRUG

Cat-PAD

1 dose every 4 weeks

DRUG

Placebo

1 dose every 4 weeks

Sponsors & Collaborators

  • inVentiv Health Clinical

    collaborator OTHER

  • Pharm-Olam International

    collaborator INDUSTRY

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Harold Nelson, MD · Jewish National Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-06-30

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01620762 on ClinicalTrials.gov